Artrya Limited Share Price

Equities

AYA

AU0000182412

Healthcare Facilities & Services

Market Closed - Australian S.E. 06:57:52 20/06/2024 BST 5-day change 1st Jan Change
0.23 AUD -4.17% Intraday chart for Artrya Limited -8.00% -4.17%

Financials

Sales 2022 - Sales 2023 - Capitalization 17.28M 25.89M 1.36B
Net income 2022 -17M -25.47M -1.34B Net income 2023 -11M -16.48M -867M EV / Sales 2022 -
Net cash position 2022 34.19M 51.23M 2.69B Net cash position 2023 19.19M 28.76M 1.51B EV / Sales 2023 -
P/E ratio 2022
-2.51 x
P/E ratio 2023
-1.55 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 55.29%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.17%
1 week-8.00%
Current month-13.21%
1 month-8.00%
3 months-17.86%
6 months+15.00%
Current year-4.17%
More quotes
1 week
0.23
Extreme 0.23
0.27
1 month
0.23
Extreme 0.23
0.30
Current year
0.19
Extreme 0.19
0.42
1 year
0.16
Extreme 0.16
0.42
3 years
0.16
Extreme 0.16
1.75
5 years
0.16
Extreme 0.16
1.75
10 years
0.16
Extreme 0.16
1.75
More quotes
Managers TitleAgeSince
Chief Executive Officer - 26/03/23
Director of Finance/CFO - 31/08/21
Chief Tech/Sci/R&D Officer - 19/06/22
Members of the board TitleAgeSince
Director/Board Member 69 31/07/22
Chairman 70 31/01/21
Director/Board Member 65 21/02/23
More insiders
Date Price Change Volume
20/06/24 0.23 -4.17% 55 832
19/06/24 0.24 0.00% 43,300
18/06/24 0.24 0.00% 112,416
17/06/24 0.24 -4.00% 3,500
13/06/24 0.25 0.00% 3,078

Delayed Quote Australian S.E., June 20, 2024 at 06:57 am

More quotes
Artrya Limited is a medical technology company focused on commercializing its artificial intelligence (AI) platform. The principal activities of the Company are the development of medical technology using AI to identify patients at risk of coronary artery disease. It is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop an overview of a patient at risk. The company has developed deep learning algorithms that allow for the prediction and prevention of acute coronary events. Its Artrya Salix is a computed tomography coronary angiography (CCTA) image analysis solution that enables physicians with AI to identify and analyze the extent and type of arterial plaque. This solution uses no external reading teams to validate cardiac scan data, allowing physicians direct control of their AI-supported patient scans. Artrya Salix provides solutions for physicians, administrators, payers and patients.
More about the company